So, doesn’t this mean the lack of previous RCT trials and the difficulty of recruiting means we are effectively running out of time because of the high cash burn rate?
Or is the German trial and adoption by BGA the key for short term cash?
Or is the deal with a strategic partner the key here?
Pancreatic Cancer in the Media, page-14
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.001(4.00%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.4¢ | 1.2¢ | $176.4K | 13.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 5353143 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 6345496 | 9 |
View Market Depth
| Last trade - 15.45pm 13/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |